FORE Issues Opinion Letter on Prescribing Buprenorphine with Telemedicine During COVID-19 Outbreak

| April 7, 2020

The COVID-19 outbreak has presented extraordinary challenges in prescribing buprenorphine to new and existing patients with opioid use disorder (OUD). Telemedicine presents an opportunity to reach these patients and promote continuity of care; however, rapidly evolving circumstances have caused confusion among many practitioners as to their rights and obligations under federal law when prescribing controlled […]

DEA Issues Proposed Rule to Expand Access to Mobile Opioid Treatment

| March 4, 2020

On February 26, 2020, DEA issued a proposed rule titled Registration Requirements for Narcotic Treatment Programs with Mobile Components. The proposed rule would waive the requirement of a separate registration for opioid treatment programs (OTPs) that utilize a mobile component. The Controlled Substances Act (CSA) generally requires, with certain exceptions, all persons who dispense controlled […]

Barnes Discusses Drug Pricing Bills in Congress on Fox Business

| December 16, 2019

Michael Barnes, JD recently made an appearance on Fox Business Live, where he discussed conflicting messages about the impact of the U.S. drug abuse crisis on corporate profits. Mr. Barnes then analyzed drug pricing bills in Congress and how they could affect Americans’ access to new medicines for conditions like Alzheimer’s and cancer. The original […]

U.S. Surgeon General: Warm Handoffs Are ‘Immediate Priority’

| October 29, 2019

On Thursday, October 24, the Senate Finance Committee held a full committee hearing on the topic of substance abuse in the United States. Among the witnesses was the Surgeon General of the United States, Jerome M. Adams, MD, MPH. Dr. Adams detailed the current approach of the Department of Health and Human Services (HHS), highlighted […]